Table 1 Patient and transplant-related characteristics of BCP- and TCP-ALL

Median follow-up (months) [95% CI]

129.3 [97.1–156]

79.4 [68.3–89.7]

0.002

Patient age (years; min-max)

40.9 (18.1–75.8)

31.9 (18.1–75.8)

< 0.001

Median year of AHSCT (IQR)

2005 (2002 - 2011)

2005 (2002 - 2011)

0.64

Median time from diagnosis to AHSCT (months; min-max)

6.5 (2.6–23.6)

6.6 (2.2–23.6)

0.21

Karnofsky performance status score:

 • < 90

40 (35.4%)

38 (17.8%)

< 0.001

 • >= 90

73 (64.6%)

175 (82.2%)

 • missing

134

240

MRD pre AHSCT:

 • MRD negative

70 (85.4%)

97 (89.8%)

0.35

 • MRD positive

12 (14.6%)

11 (10.2%)

 • missing

165

345

Median WBC at diagnosis (G/L; min-max)

88 (1–184)

96.5 (1–186)

0.092

Patient sex:

 • Male

141 (57.1%)

338 (74.6%)

< 0.001

 • Female

106 (42.9%)

115 (25.4%)

Cells source

 • BM

18 (7.3%)

31 (6.9%)

0.83

 • PB

229 (92.7%)

421 (93.1%)

 • Missing

0

1

Karyotype:

 • Normal

115 (51.6%)

103 (59.9%)

0.1

 • Abnormal

108 (48.4%)

69 (40.1%)

 • Not done/Failed

24

281

Conditioning:

 • TBI-based

98 (39.7%)

206 (45.5%)

0.14

 • CT-based

149 (60.3%)

247 (54.5%)

Dose of TBI (Gy)

 • 8–10

12 (12.9%)

16 (11.9%)

0.86

 • 12

72 (77.4%)

103 (76.3%)

 • 13–14

9 (9.7%)

16 (11.9%)

 • Missing

154

318

Engraftment:

 • Graft failure

1 (0.4%)

8 (1.8%)

0.13

 • Engrafted

239 (99.6%)

442 (98.2%)

 • Missing

7

3